Current Rating and Its Significance
MarketsMOJO’s 'Hold' rating for Suraksha Diagnostic Ltd indicates a neutral stance on the stock, suggesting that investors should maintain their existing positions rather than aggressively buying or selling. This rating reflects a balanced view of the company’s prospects, considering both strengths and challenges in its financial and market performance. The rating was adjusted from 'Sell' to 'Hold' on 12 May 2026, following an improvement in the company’s overall Mojo Score from 44 to 54, signalling a moderate enhancement in its investment appeal.
Here’s How the Stock Looks Today
As of 24 May 2026, Suraksha Diagnostic Ltd is classified as a microcap company operating within the Healthcare Services sector. The stock has experienced mixed returns over various time frames: a one-day decline of 4.05%, but positive momentum over the past month (+8.69%) and year-to-date gains of 14.47%. Despite this, the stock’s one-year return remains negative at -5.54%, reflecting some volatility and underperformance relative to broader benchmarks such as the BSE500.
Quality Assessment
The company’s quality grade is rated as 'good', underpinned by a strong ability to service its debt obligations. Suraksha Diagnostic Ltd maintains a low Debt to EBITDA ratio of 1.40 times, indicating manageable leverage and financial stability. Additionally, the company has demonstrated healthy long-term growth, with operating profit expanding at an annualised rate of 60.46%. This robust growth trajectory highlights the company’s operational efficiency and potential for sustained earnings expansion.
Valuation Considerations
Currently, the valuation grade is assessed as 'fair'. The company’s Return on Capital Employed (ROCE) stands at a respectable 15.8%, which supports a reasonable valuation multiple. The Enterprise Value to Capital Employed ratio is 5.5, suggesting that the stock is priced moderately relative to the capital it utilises. However, the Price/Earnings to Growth (PEG) ratio is notably high at 26.8, signalling that the stock may be expensive when factoring in its earnings growth rate. Investors should weigh this valuation against the company’s growth prospects and sector dynamics.
Financial Trend Analysis
The financial grade is currently negative, reflecting some recent operational challenges. The latest quarterly results ending March 2026 reveal a decline in profitability, with the operating profit to interest coverage ratio dropping to 6.22 times, the lowest in recent quarters. Profit After Tax (PAT) for the quarter was ₹6.28 crores, down 24.6% compared to the previous four-quarter average. Furthermore, the debt-equity ratio has increased to 0.51 times at the half-year mark, the highest level recorded recently, indicating a slight rise in financial leverage. Despite these setbacks, the company’s profits have grown by 2% over the past year, suggesting some resilience amid headwinds.
Technical Outlook
Technically, the stock is graded as mildly bullish. While the one-day price movement was negative (-4.05%), the stock has shown positive trends over the medium term, including a 3-month gain of 8.88% and a 6-month increase of 2.54%. This technical momentum may offer some support to the stock price, although investors should remain cautious given the recent volatility and mixed financial signals.
Institutional Interest and Market Position
Institutional investors hold a significant stake in Suraksha Diagnostic Ltd, with 36.59% ownership as of the latest data. This level of institutional holding is often viewed positively, as these investors typically possess greater resources and expertise to analyse company fundamentals. Notably, institutional holdings have increased by 0.56% over the previous quarter, signalling continued confidence from sophisticated market participants. However, the stock has consistently underperformed the BSE500 benchmark over the past three years, which may temper enthusiasm among some investors.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
What This Rating Means for Investors
The 'Hold' rating suggests that Suraksha Diagnostic Ltd currently presents a balanced risk-reward profile. Investors holding the stock may consider maintaining their positions while monitoring upcoming financial results and market developments closely. The company’s strong quality metrics and moderate valuation provide some comfort, but the recent negative financial trends and underperformance relative to benchmarks warrant caution. New investors might prefer to wait for clearer signs of sustained improvement before initiating positions.
Summary of Key Metrics as of 24 May 2026
To recap, the stock’s key performance indicators include a Mojo Score of 54.0, reflecting a moderate investment appeal. The stock’s returns over various periods show mixed results, with a 1-year return of -5.54% contrasting with a positive year-to-date gain of 14.47%. The company’s debt metrics remain manageable, but recent quarterly profitability has weakened. Institutional confidence remains relatively strong, which may provide some stability amid market fluctuations.
Outlook and Considerations
Looking ahead, investors should watch for improvements in quarterly earnings and operating margins, as well as any changes in leverage or capital structure. The healthcare services sector remains competitive, and Suraksha Diagnostic Ltd’s ability to sustain growth and improve financial trends will be critical to its future rating and market performance. Given the current data, the 'Hold' rating appropriately reflects a cautious but not pessimistic stance on the stock.
Conclusion
Suraksha Diagnostic Ltd’s current 'Hold' rating by MarketsMOJO, updated on 12 May 2026, is supported by a combination of good quality fundamentals, fair valuation, a negative but stabilising financial trend, and mildly bullish technical indicators. Investors should consider these factors carefully in the context of their portfolio objectives and risk tolerance, recognising that the stock’s recent performance has been mixed but shows potential for recovery.
Only Rs. 20,999 - Get MojoOne + Stock of the Week for 3 Years Get 71% Off →
